Posters

    6-Aryl-β-Carbolines As Potent Tubulin-Polymerization Inhibitors

    Blaney, P.; Foster, S.; Blaney, E.; Hallworth, S.; Smith, A.; Doyle, P.; Fisher, R.; Teichert, A.; Lang, G.; Demotz, S.; McHugh, D.; Pospisil, P.; Goffman, F.

    Conference date
    May 9, 2013
    Conference name
    Grasmere Heterocyclic and Synthesis Meeting (RSC)
    Link to more information
    Summary

    Natural products have proven to be an excellent resource for discovering new potential drug candidates. For example, a recent study has shown that 64% of anti-cancer drugs and 76% of anti-bacterial drugs are natural products or derivatives. 1. Within a program aimed at the exploration of the biological activities of semisynthetic libraries based on natural product scaffolds – one of which was harmane 1 – 6-aryl-β-carbolines 2. Were identified as potent cytotoxic agents with an in vivo anti-tumour activity. The underlying mechanism was found to be microtubulin depolymerization by interaction with the colchicine binding site. 

    Related Publications

    Nicotine Pharmacokinetics and Subjective Effects of Nicotine Pouch 1.0 Compared to Velo® Ice Cool and Zyn® Cool Mint Mini Dry in Healthy Smokers

    Clinical Studies

    Nicotine Pharmacokinetics Following Use of the P4M3 Gen 2.0 E-Cigarette Compared to Smoking Cigarettes

    Clinical Studies

    International Expert Consensus on Relevant Health and Functioning Concepts to Assess in Users of Tobacco and Nicotine Products: Delphi Study

    Smoke-free products;Perception and Behavior

    A comparative assessment of HPHC yields and in vitro toxicity for 1R6F reference cigarette smoke versus aerosol generated by Tobacco Heating System 3.0

    Pre-clinical Toxicology

    An In Vitro Systems Toxicology Assessment of Novel Electronic Vapor Device by Using Air–Liquid Interface Buccal, Bronchial, Small Airway, and Alveolar Culture Models

    Systems Toxicology

    Assessment of the Effects of Acute and Continuous Exposure to Tobacco Heating System 2.4 and Cigarette Smoke Total Particulate Matter on a Direct 2D Osteoblast/Osteoclast Coculture Model

    Pre-clinical Toxicology;Systems Toxicology

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.